Editors' Desk

1. Can AMTs Make U.S. Pharmaceuticals Faster, Better, Stronger? 7/11/2025

   As the pharmaceutical industry prepares for impending tariffs and invests in domestic manufacturing, advanced manufacturing technologies present a viable opportunity to modernize systems for improved efficiency, consistent quality and potentially lower costs.

2. How Modular Facility Design Can Accelerate GMP Facility Construction 5/20/2025

   Autolus Therapeutics' COO talks about the accelerated construction of the company's cell therapy manufacturing facility, The Nucleus.

3. A Facilities Expert Answers Audience Questions On Construction And Validation 5/5/2025

   Bioprocessing facility expert Herman Bozenhardt responds to some unanswered audience questions from a Pharmaceutical Online Live event on facility design and validation.

4. Experts' Advice On Facility Design And Construction 4/24/2025

   This is a review of the Pharmaceutical Online Live event “Facility Design And Validation Considerations For Drug Manufacturers," which featured industry experts Erich Bozenhardt and Herman Bozenhardt, as well as process architect Fred Grossfeld.

5. Areas For Advancement In Peptide Manufacturing 2/27/2025

   Experts from Eli Lilly, NervGen, and Piramal Pharma Solutions discuss the myriad of ways peptide manufacturing can be improved, drawing on years of industry experience and insight.

6. For Gilead, Sustainability Is More Than A PR Effort 2/14/2025

   Gilead's chief sustainability officer and SVP of operations, Joydeep Ganguly, explains the company's cultural focus on sustainability and how it influences everything from R&D to manufacturing. 

7. Antibodies 2025: Venerable & Naked Or Complex & Multi-Specific? 12/19/2024

   Antibodies are the biotherapeutic bulwark, the steadfast stalwart in not just oncology, but infectious and chronic inflammatory diseases as well. We consulted with a variety of antibody developers for insight into the challenges and opportunities antibody modalities face in the coming year and beyond.

8. The ADC Market Is Ripening For Disruption 8/21/2024

   Where there is therapeutic demand, the industry will build capacity. But with ADCs, cytotoxic payloads and a fragmented contract manufacturing landscape make the path to clinical and commercial supply dauntingly complicated. Here's how the ADC manufacturing market is shaping up, and how it might ultimately shake out.

9. Are You Taking The HPCs In Your ADCs Seriously? 8/16/2024

   The wave of ADC (antibody-drug conjugate) development and manufacturing activity we’re currently witnessing, and importantly, the HPC (high-potency compounds) comprising the payloads in these therapies, demand thorough assessment of development and manufacturing facility design.

10. BPSA's Single-Use Summit Celebrates Its "Stainless" Anniversary 7/29/2024

    The Bio Process Systems Alliance (BPSA) is devoted to the advance of single-use technologies in biopharmaceutical manufacturing. At its 11th International Single-Use Summit, the explosive growth in single-use was on full display, and the sourcing, safety, sustainability, and application discussions on the agenda were comprehensive.